# Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

> **NCT03602339** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 157 (actual)

## Conditions studied

- Magnetic Resonance Imaging

## Interventions

- **DRUG:** Gadoterate (Dotarem/Clariscan)
- **DRUG:** Gadobutrol (Gadavist/Gadovist, BAY86-4875)

## Key facts

- **NCT ID:** NCT03602339
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-14
- **Primary completion:** 2020-03-13
- **Final completion:** 2020-05-26
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602339, "Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03602339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*